Cargando…

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial

PURPOSE: We aimed to discuss the roles of radiation and chemotherapy as adjuvant treatment in patients with staged IB GC who were enrolled in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. MATERIALS AND METHODS: Among the 458 patients who were enrolled in the ARTIST trial, 99 had s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youjin, Kim, Kyoung-Mee, Choi, Min Gew, Lee, Jun Ho, Sohn, Tae Sung, Bae, Jae Moon, Kim, Sung, Lee, Su Jin, Kim, Seung Tae, Lee, Jeeyun, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310765/
https://www.ncbi.nlm.nih.gov/pubmed/30607298
http://dx.doi.org/10.5230/jgc.2018.18.e34
_version_ 1783383491473309696
author Kim, Youjin
Kim, Kyoung-Mee
Choi, Min Gew
Lee, Jun Ho
Sohn, Tae Sung
Bae, Jae Moon
Kim, Sung
Lee, Su Jin
Kim, Seung Tae
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Park, Se Hoon
author_facet Kim, Youjin
Kim, Kyoung-Mee
Choi, Min Gew
Lee, Jun Ho
Sohn, Tae Sung
Bae, Jae Moon
Kim, Sung
Lee, Su Jin
Kim, Seung Tae
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Park, Se Hoon
author_sort Kim, Youjin
collection PubMed
description PURPOSE: We aimed to discuss the roles of radiation and chemotherapy as adjuvant treatment in patients with staged IB GC who were enrolled in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. MATERIALS AND METHODS: Among the 458 patients who were enrolled in the ARTIST trial, 99 had stage IB disease. The patients were randomly assigned to receive either adjuvant chemoradiotherapy with capecitabine plus cisplatin (XP, n=50) or chemoradiotherapy (XPRT, n=49). Survival analyses were performed in accordance with the AJCC 2010 staging system. RESULTS: According to the AJCC 2010 system, stage migration from IB to II occurred in 71% of the patients; 98% of the T2 N0 cases were reclassified as T3 N0, and 42% of the T1 N1 cases were reclassified as T1 N2. When comparing survival outcomes between the XPRT and XP arms for stage IB cancer (AJCC 2002), no significant difference in 5-year disease-free survival (DFS) between the 2 arms was found. (median 5-year DFS, not reached, P=0.256). The patients classified as having stage IB cancer (AJCC 2002) and reclassified as having stage II cancer (AJCC 2010) exhibited worse prognoses than those who remained in stage IB, although the difference was not statistically significant (5-year DFS rate, 83% vs. 93%). When we compared 5-year DFS in 70 patients with stage II (AJCC 2010), the addition of radiotherapy to XP chemotherapy did not show better outcome than XP alone (P=0.137). CONCLUSIONS: The role of adjuvant chemoradiotherapy in the treatment of stage IB GC (AJCC 2002) warrants further investigation.
format Online
Article
Text
id pubmed-6310765
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Gastric Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-63107652019-01-03 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim, Youjin Kim, Kyoung-Mee Choi, Min Gew Lee, Jun Ho Sohn, Tae Sung Bae, Jae Moon Kim, Sung Lee, Su Jin Kim, Seung Tae Lee, Jeeyun Park, Joon Oh Park, Young Suk Lim, Ho Yeong Kang, Won Ki Park, Se Hoon J Gastric Cancer Original Article PURPOSE: We aimed to discuss the roles of radiation and chemotherapy as adjuvant treatment in patients with staged IB GC who were enrolled in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. MATERIALS AND METHODS: Among the 458 patients who were enrolled in the ARTIST trial, 99 had stage IB disease. The patients were randomly assigned to receive either adjuvant chemoradiotherapy with capecitabine plus cisplatin (XP, n=50) or chemoradiotherapy (XPRT, n=49). Survival analyses were performed in accordance with the AJCC 2010 staging system. RESULTS: According to the AJCC 2010 system, stage migration from IB to II occurred in 71% of the patients; 98% of the T2 N0 cases were reclassified as T3 N0, and 42% of the T1 N1 cases were reclassified as T1 N2. When comparing survival outcomes between the XPRT and XP arms for stage IB cancer (AJCC 2002), no significant difference in 5-year disease-free survival (DFS) between the 2 arms was found. (median 5-year DFS, not reached, P=0.256). The patients classified as having stage IB cancer (AJCC 2002) and reclassified as having stage II cancer (AJCC 2010) exhibited worse prognoses than those who remained in stage IB, although the difference was not statistically significant (5-year DFS rate, 83% vs. 93%). When we compared 5-year DFS in 70 patients with stage II (AJCC 2010), the addition of radiotherapy to XP chemotherapy did not show better outcome than XP alone (P=0.137). CONCLUSIONS: The role of adjuvant chemoradiotherapy in the treatment of stage IB GC (AJCC 2002) warrants further investigation. The Korean Gastric Cancer Association 2018-12 2018-11-16 /pmc/articles/PMC6310765/ /pubmed/30607298 http://dx.doi.org/10.5230/jgc.2018.18.e34 Text en Copyright © 2018. Korean Gastric Cancer Association https://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Youjin
Kim, Kyoung-Mee
Choi, Min Gew
Lee, Jun Ho
Sohn, Tae Sung
Bae, Jae Moon
Kim, Sung
Lee, Su Jin
Kim, Seung Tae
Lee, Jeeyun
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Park, Se Hoon
Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title_full Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title_fullStr Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title_full_unstemmed Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title_short Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
title_sort adjuvant chemotherapy with or without concurrent radiotherapy for patients with stage ib gastric cancer: a subgroup analysis of the adjuvant chemoradiotherapy in stomach tumors (artist) phase iii trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310765/
https://www.ncbi.nlm.nih.gov/pubmed/30607298
http://dx.doi.org/10.5230/jgc.2018.18.e34
work_keys_str_mv AT kimyoujin adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT kimkyoungmee adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT choimingew adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT leejunho adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT sohntaesung adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT baejaemoon adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT kimsung adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT leesujin adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT kimseungtae adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT leejeeyun adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT parkjoonoh adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT parkyoungsuk adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT limhoyeong adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT kangwonki adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial
AT parksehoon adjuvantchemotherapywithorwithoutconcurrentradiotherapyforpatientswithstageibgastriccancerasubgroupanalysisoftheadjuvantchemoradiotherapyinstomachtumorsartistphaseiiitrial